Leucine-rich Alpha-2 glycoprotein could be clinically useful in active and postoperative Crohn's disease

被引：0

作者：

Tashiro, Taku ^{[1
]}

Shinzaki, Shinichiro ^{[1
,2
]}

Yoshihara, Takeo ^{[1
]}

Tsujii, Yuri ^{[1
]}

Asakura, Akiko ^{[1
]}

Amano, Takahiro ^{[1
]}

Tani, Mizuki ^{[1
]}

Otake-Kasamoto, Yuriko ^{[1
]}

Uema, Ryotaro ^{[1
]}

Tsujii, Yoshiki ^{[1
]}

Inoue, Takahiro ^{[1
]}

Ogino, Takayuki ^{[3
]}

Iijima, Hideki ^{[1
,4
]}

Hayashi, Yoshito ^{[1
]}

Takehara, Tetsuo ^{[1
]}

机构：

[1] Osaka Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan

[2] Hyogo Med Univ, Dept Gastroenterol, Fac Med, Nishinomiya, Japan

[3] Osaka Univ, Grad Sch Med, Dept Gastroenterol Surg, Suita, Osaka, Japan

[4] Osaka Keisatsu Hosp, Dept Internal Med, Osaka, Japan

来源：

SCIENTIFIC REPORTS | 2025年 / 15卷 / 01期

关键词：

C-REACTIVE PROTEIN; CAPSULE ENDOSCOPY; BIOMARKER; SURGERY;

D O I：

10.1038/s41598-025-93831-7

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

The clinical usefulness of serum leucine-rich alpha-2 glycoprotein (LRG) levels as a surrogate marker of endoscopic activity including postoperative recurrence in patients with Crohn's disease (CD) remains unclear, and LRG production in the small intestinal mucosa has not been explored. The present study investigated the usefulness of serum LRG to ascertain endoscopic activity, the secretion of LRG from the small intestinal mucosa, and the significance of LRG as a predictor of postoperative disease course. We included 364 patients who underwent transanal endoscopy at Osaka University Hospital. Serum LRG correlated highly with endoscopic severity (LRG, r = 0.65; CRP, r = 0.37) and reflected strictly moderate endoscopic activity better than serum CRP. Especially, serum LRG reflected mucosal healing even in patients whose inflammation was confined to the small intestine. In multivariate analyses, serum LRG was an independent factor influencing mucosal healing. LRG was more strongly expressed in the inflamed mucosa of the small intestine compared with that in uninflamed mucosa, and serum LRG was more strongly correlated with postoperative small intestinal recurrence severity than CRP (LRG, r = 0.62; CRP, r = 0.32). In conclusion, serum LRG is a useful surrogate marker of endoscopic CD severity and activity, with increased LRG expression in the small bowel predicting postoperative recurrence.

引用

页数：10

共 33 条

[11] Omori T., Et al., Serum Leucine-Rich Alpha-2 Glycoprotein in Quiescent Crohn’s Disease as a Potential Surrogate Marker for Small-Bowel Ulceration detected by Capsule Endoscopy, J. Clin. Med, 11, (2022)
[12] Shinzaki S., Et al., Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study, J. Gastroenterol, 56, pp. 560-569, (2021)
[13] Abe I., Et al., Serum leucine-rich alpha-2 glycoprotein as a predictive factor of endoscopic remission in Crohn’s disease, J. Gastroenterol. Hepatol, (2022)
[14] Kusaka J., Et al., Residual lesions on capsule endoscopy is associated with postoperative clinical recurrence in patients with Crohn’s disease, Dig. Dis. Sci, 63, pp. 768-774, (2018)
[15] Kono T., Et al., Prospective postsurgical capsule endoscopy in patients with Crohn’s disease, World J. Gastrointest. Endosc, 6, pp. 88-98, (2014)
[16] De Cruz P., Kamm M.A., Prideaux L., Allen P.B., Moore G., Mucosal healing in Crohn’s disease: a systematic review, Inflamm. Bowel Dis, 19, pp. 429-444, (2013)
[17] Buisson A., Chevaux J.B., Allen P.B., Bommelaer G., Peyrin-Biroulet, L. Review Article: the natural history of postoperative Crohn’s disease recurrence, Aliment. Pharmacol. Ther, 35, pp. 625-633, (2012)
[18] Yamamoto T., Watanabe T., Surgery for luminal Crohn’s disease, World J. Gastroenterol, 20, pp. 78-90, (2014)
[19] Serada S., Et al., Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis, Inflamm. Bowel Dis, 18, pp. 2169-2179, (2012)
[20] Feagan B., Et al., Performance of Crohn’s disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: analysis of EXTEND data, Inflamm. Bowel Dis, 24, pp. 932-942, (2018)

← 1 2 3 4 →